Targeting high-density lipoproteins to reduce cardiovascular risk: what is the evidence?

PJ Barter, KA Rye - Clinical therapeutics, 2015 - Elsevier
Purpose This article reviews therapies that affect HDLs. Findings Lipid-modifying agents in
current use (including statins, fibrates, and niacin) increase the concentration of HDL …
被引用次数：36 相关文章

Targeting High-density Lipoproteins to Reduce Cardiovascular Risk: What Is the Evidence?

PJ Barter, KA Rye - Clinical Therapeutics, 2015 - clinicaltherapeutics.com
Purpose This article reviews therapies that affect HDLs. Findings Lipid-modifying agents in
current use (including statins, fibrates, and niacin) increase the concentration of HDL …

Targeting High-density Lipoproteins to Reduce Cardiovascular Risk: What Is the Evidence?

PJ Barter, KA Rye - Clinical Therapeutics, 2015 - infona.pl
This article reviews therapies that affect HDLs. Lipid-modifying agents in current use
(including statins, fibrates, and niacin) increase the concentration of HDL cholesterol to …

Targeting High-density Lipoproteins to Reduce Cardiovascular Risk: What Is the Evidence?

PJ Barter, KA Rye - Clinical Therapeutics, 2015 - europepmc.org
Implications Positive trials with reconstituted HDL infusions and reinfusions of selectively
delipidated plasma will establish HDLs as important therapeutic targets. However, although …

Targeting high-density lipoproteins to reduce cardiovascular risk: what is the evidence?

PJ Barter, KA Rye - 2015 - cabidigitallibrary.org
Purpose: This article reviews therapies that affect HDLs. Findings: Lipid-modifying agents in
current use (including statins, fibrates, and niacin) increase the concentration of HDL …

Targeting High-density Lipoproteins to Reduce Cardiovascular Risk: What Is the Evidence?

PJ Barter, KA Rye - Clinical therapeutics, 2015 - pubmed.ncbi.nlm.nih.gov
Purpose This article reviews therapies that affect HDLs. Findings Lipid-modifying agents in
current use (including statins, fibrates, and niacin) increase the concentration of HDL …

[引用][C] Targeting High-density Lipoproteins to Reduce Cardiovascular Risk: What Is the Evidence?

PJ Barter, KA Rye - Clinical Therapeutics, 2015 - Elsevier Limited